|
| % (95% CI) | |
Sensitivity | Specificity | AUC (95% CI) | Target condition | DR grading scale |
|
Gulshan et al. [24] | 97.5 (95.8–98.7) | 93.4 (92.8–94.0) | — | Moderate or worse DR, referable DMO, or both | ICDR |
Gulshan et al. [32] | 92.1 (90.1–93.8) | 95.2 (94.2–96.1) | 0.980 | Moderate or worse DR | ICDR |
Krause et al. [33] | 97.1 | 92.3 | 0.986 | Moderate or worse DR | ICDR |
Ruamviboonsuk et al. [34] | 96.8 (93.9–100) | 95.6 (98.3–96.8) | 0.987 (0.977–0.995) | Moderate or worse DR | ICDR |
Voets et al. [35] | 90.6 | 84.7 | 0.951 (0.947–0.956) | Moderate or worse DR | ICDR |
Ramachandran et al. [36] | 96.0 | 90.0 | 0.980 (0.973–0.986) | Moderate or worse DR, or exudates in 1 disc diameter of the fovea | ICDR and NZ MoH guidelines |
Li et al. [37] | 97.0 | 91.4 | 0.989 | Preproliferative or worse DR, DMO, or both | NHS diabetic eye screening guidelines |
Gargeya et al. [38] | 93.0 | 87.0 | 0.940 | No DR or any DR | — |
Abràmoff et al. [39] | 96.8 (93.3–98.8) | 87.0 (84.2–89.4) | 0.980 (0.968–0.992) | Moderate or worse DR, DMO, or both | ICDR |
Verbraak et al. [40] | 79.4 (66.5–87.9) | 93.8 (92.1–94.9) | — | More than mild DR | ICDR |
Abràmoff et al. [41] | 87.2 (81.8–91.2) | 90.7 (88.3–92.7) | — | More than mild, or DMO, or both | ETDRS |
Ting et al. [42] | 98.9 (97.5–99.6) | 92.2 (89.5–94.3) | 0.983 (0.972–0.991) | Moderate or worse DR, DMO, and/or ungradable image | ICDR |
Bellemo et al. [43] | 92.3 (90.1–94.1) | 89.0 (87.9–90.3) | 0.973 (0.969–0.978) | Moderate or worse DR, DMO, and/or ungradable image | ICDR |
Rogers et al. [44] | 93.4% (95% CI: 90.8–95.8) | 94.2% (95% CI: 91.0–97.2) | 98.5% (95% CI: 97.8–99.2) | Referable DR (RDR) and proliferative DR (PDR) | Scottish DR grading scheme |
Bhaskaranand et al. [45] | 91.3% (95% CI: 90.9%–91.7%) | 91.1% (95% CI: 90.9%–91.3%) | 0.965 (95% CI: 0.963–0.966) | Severe NPDR, proliferative DR | American academy of ophthalmology |
|